DK3104872T3 - Paricalcitol til anvendelse ved behandling af inflammatorisk - Google Patents
Paricalcitol til anvendelse ved behandling af inflammatorisk Download PDFInfo
- Publication number
- DK3104872T3 DK3104872T3 DK15702156.9T DK15702156T DK3104872T3 DK 3104872 T3 DK3104872 T3 DK 3104872T3 DK 15702156 T DK15702156 T DK 15702156T DK 3104872 T3 DK3104872 T3 DK 3104872T3
- Authority
- DK
- Denmark
- Prior art keywords
- inflammatoric
- paricalcitol
- treatment
- Prior art date
Links
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 title 1
- 229960000987 paricalcitol Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430177A ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
| PCT/EP2015/050817 WO2015121022A1 (en) | 2014-02-11 | 2015-01-16 | Use of paricalcitol in the treatment of inflammatory anaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3104872T3 true DK3104872T3 (da) | 2019-06-17 |
Family
ID=51205045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15702156.9T DK3104872T3 (da) | 2014-02-11 | 2015-01-16 | Paricalcitol til anvendelse ved behandling af inflammatorisk |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11464791B2 (enExample) |
| EP (1) | EP3104872B1 (enExample) |
| JP (1) | JP2017512753A (enExample) |
| KR (1) | KR20160113664A (enExample) |
| CN (1) | CN106061498B (enExample) |
| AR (1) | AR099330A1 (enExample) |
| AU (1) | AU2015217956B2 (enExample) |
| CA (1) | CA2938057A1 (enExample) |
| DK (1) | DK3104872T3 (enExample) |
| ES (2) | ES2472040B1 (enExample) |
| IL (1) | IL247207B (enExample) |
| MX (1) | MX365096B (enExample) |
| PT (1) | PT3104872T (enExample) |
| RU (1) | RU2016131412A (enExample) |
| UY (1) | UY35989A (enExample) |
| WO (1) | WO2015121022A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102504090B1 (ko) * | 2020-08-05 | 2023-02-24 | 경상국립대학교병원 | 조영제-유발 신독성 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004062620A2 (en) * | 2003-01-13 | 2004-07-29 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
| CA2563874A1 (en) * | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
| CN101610782A (zh) * | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
| CN102772364B (zh) * | 2011-05-13 | 2015-12-02 | 重庆华邦制药有限公司 | 帕立骨化醇的脂肪乳及其制剂和制备方法 |
-
2014
- 2014-02-11 ES ES201430177A patent/ES2472040B1/es not_active Expired - Fee Related
-
2015
- 2015-01-16 CN CN201580007824.4A patent/CN106061498B/zh active Active
- 2015-01-16 US US15/117,896 patent/US11464791B2/en active Active
- 2015-01-16 CA CA2938057A patent/CA2938057A1/en not_active Abandoned
- 2015-01-16 RU RU2016131412A patent/RU2016131412A/ru unknown
- 2015-01-16 ES ES15702156T patent/ES2728158T3/es active Active
- 2015-01-16 DK DK15702156.9T patent/DK3104872T3/da active
- 2015-01-16 EP EP15702156.9A patent/EP3104872B1/en active Active
- 2015-01-16 PT PT15702156T patent/PT3104872T/pt unknown
- 2015-01-16 KR KR1020167023202A patent/KR20160113664A/ko not_active Ceased
- 2015-01-16 AU AU2015217956A patent/AU2015217956B2/en active Active
- 2015-01-16 JP JP2016552329A patent/JP2017512753A/ja active Pending
- 2015-01-16 WO PCT/EP2015/050817 patent/WO2015121022A1/en not_active Ceased
- 2015-01-16 MX MX2016010104A patent/MX365096B/es active IP Right Grant
- 2015-02-10 UY UY35989A patent/UY35989A/es not_active Application Discontinuation
- 2015-02-10 AR ARP150100380A patent/AR099330A1/es unknown
-
2016
- 2016-08-10 IL IL247207A patent/IL247207B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2472040R1 (es) | 2014-09-18 |
| IL247207B (en) | 2020-02-27 |
| US11464791B2 (en) | 2022-10-11 |
| AU2015217956B2 (en) | 2019-04-04 |
| ES2728158T3 (es) | 2019-10-22 |
| US20160367571A1 (en) | 2016-12-22 |
| ES2472040B1 (es) | 2015-07-01 |
| RU2016131412A (ru) | 2018-03-15 |
| CN106061498A (zh) | 2016-10-26 |
| MX365096B (es) | 2019-05-22 |
| JP2017512753A (ja) | 2017-05-25 |
| CA2938057A1 (en) | 2015-08-20 |
| UY35989A (es) | 2015-03-27 |
| ES2472040A2 (es) | 2014-06-27 |
| KR20160113664A (ko) | 2016-09-30 |
| CN106061498B (zh) | 2019-12-06 |
| AR099330A1 (es) | 2016-07-13 |
| IL247207A0 (en) | 2016-09-29 |
| PT3104872T (pt) | 2019-06-11 |
| MX2016010104A (es) | 2017-01-06 |
| WO2015121022A1 (en) | 2015-08-20 |
| EP3104872A1 (en) | 2016-12-21 |
| AU2015217956A1 (en) | 2016-08-25 |
| EP3104872B1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3718507T3 (da) | Anordninger til behandling af nedre ekstremitetsvaskulatur | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3221359T3 (da) | Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof | |
| DK3193929T3 (da) | Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3172227T3 (da) | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme | |
| DK3256853T3 (da) | Forudsigelse af t-celleepitoper, der er egnede til vaccination | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3261726T3 (da) | Sammensætning til behandling af acne | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3122308T3 (da) | Indretning til behandling af smerte |